| Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences A Zhu, JG Ibrahim, MI Love Bioinformatics 35 (12), 2084-2092, 2019 | 1472 | 2019 |
| Nonparametric expression analysis using inferential replicate counts A Zhu, A Srivastava, JG Ibrahim, R Patro, MI Love Nucleic Acids Research 47 (18), e105, 2019 | 98 | 2019 |
| MRLocus: Identifying causal genes mediating a trait through Bayesian estimation of allelic heterogeneity A Zhu, N Matoba, EP Wilson, AL Tapia, Y Li, JG Ibrahim, JL Stein, MI Love PLoS genetics 17 (4), e1009455, 2021 | 37 | 2021 |
| A national cross-sectional survey of financial toxicity among bladder cancer patients M Ehlers, M Bjurlin, J Gore, R Pruthi, G Narang, R Tan, M Nielsen, A Zhu, ... Urologic Oncology: Seminars and Original Investigations 39 (1), 76. e1-76. e7, 2021 | 30 | 2021 |
| Acute Myeloid Leukemia with Co‐mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic … SM Johnson, DR Richardson, J Galeotti, S Esparza, A Zhu, Y Fedoriw, ... Hemasphere 3 (5), e292, 2019 | 13 | 2019 |
| Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia LM Garner, T Kline, J Miller, A Deal, A Zhu, MR Sketch, CC Coombs, ... Journal of the Advanced Practitioner in Oncology 12 (1), 20, 2021 | 7 | 2021 |
| Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases LEM Castillo, S Palmer, A Deal, SL Chen, A Zhu, S Moll Blood 134, 390, 2019 | 6* | 2019 |
| A super‐combo‐drug test to detect adverse drug events and drug interactions from electronic health records in the era of polypharmacy A Zhu, D Zeng, L Shen, X Ning, L Li, P Zhang Statistics in Medicine 39 (10), 1458-1472, 2020 | 3 | 2020 |
| Response to tyrosine kinase inhibitors in real-world patients with chronic myeloid leukemia AH Szeto, T Bucci, A Deal, A Zhu, M Ahmad, AS Cass, MR Sketch, ... Annals of Pharmacotherapy 56 (7), 753-763, 2022 | 2 | 2022 |
| Estimating causal log-odds ratio using the case-control sample and its application in the pharmaco-epidemiology study A Zhu, D Zeng, P Zhang, L Li Statistical methods in medical research 28 (7), 2165-2178, 2019 | 2 | 2019 |
| Accelerated drug resistant variant discovery with an enhanced, scalable mutagenic base editor platform BH KM Dorighi*, A Zhu*, JP Fortin, J Lo, J Sudhamsu, S Durinck, M Callow, S ... BioRxiv, 2023 | 1* | 2023 |
| Adherence to infectious disease screening and immunization guidelines when treating non‐malignant immune‐mediated hematologic disorders LE Malpica‐Castillo, S Palmer, A Zhu, AM Deal, SL Chen, S Moll American journal of hematology 95 (3), E72-E75, 2020 | 1 | 2020 |
| INNV-43. IMPROVING POST OPERATIVE FOLLOW-UP AND TIME TO ADJUVANT TREATMENT FOR HIGH GRADE GLIOMA M Catalino, D Zeitouni, S Henretty, A Zhu, S Khagi Neuro-Oncology 21 (Supplement_6), vi139, 2019 | 1 | 2019 |
| Improving Postoperative Multidisciplinary Care Coordination for Patients with Gliomas SK Daniel Zeitouni, Michael P. Catalino, Anqi Zhu Journal of Oncology Navigation and Survivorship 11 (7), 2020 | | 2020 |
| Package ‘fishpond’ A Zhu, A Srivastava, J Ibrahim, R Patro, M Love, MM Love | | 2020 |
| Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia B Muluneh, C Coombs, L Drawdy, T Kline, A Deal, A Zhu, J Miller, ... LEUKEMIA & LYMPHOMA 61, 119-119, 2020 | | 2020 |
| Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders LEM Castillo, S Palmer, A Zhu, A Deal, SL Chen, S Moll Blood 134, 792, 2019 | | 2019 |
Joseph G. IbrahimUNCVerified email at bios.unc.edu
